Women'S Choice Patent-Cliff Exposure & CMS Drug Spending Portfolio

Women'S Choice (US): 4 reconciled FDA prescription therapies, $451K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$451K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$451K
California HCAI SB 17 Filings0 statutory filings in 2023 to 2026 panel